Cargando…

RAD51AP1在肿瘤进展和耐药中的研究进展

The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported...

Descripción completa

Detalles Bibliográficos
Autores principales: LIU, Renwang, LI, Mingbiao, HU, Zixuan, SONG, Zuoqing, CHEN, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600754/
https://www.ncbi.nlm.nih.gov/pubmed/37985156
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34
_version_ 1785126054494470144
author LIU, Renwang
LI, Mingbiao
HU, Zixuan
SONG, Zuoqing
CHEN, Jun
author_facet LIU, Renwang
LI, Mingbiao
HU, Zixuan
SONG, Zuoqing
CHEN, Jun
author_sort LIU, Renwang
collection PubMed
description The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported as an essential protein for maintaining cellular genomic stability. However, recent studies showed that RAD51AP1 was significantly overexpressed in various cancer types and correlated with poor prognosis. These results suggested that RAD51AP1 may play a significant pro-cancer effect in multiple cancers. The underlying mechanism is still unclear. Cancer stemness-maintaining effects of RAD51AP1 might be considered as the most reliable mechanism. Meanwhile, RAD51AP1 also promoted resistance to radiation therapy and chemotherapy in many cancers. Thus, researches focused on RAD51AP1, and its regulatory molecules may provide new targets for overcoming cancer progression and treatment resistance. Here, we reviewed the latest research on RAD51AP1 in cancers and summarized its differential expression and prognostic implications. In this review, we also outlined the potential mechanisms of its pro-cancer and drug resistance-promoting effects to provide several potential directions for further research.
format Online
Article
Text
id pubmed-10600754
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-106007542023-10-27 RAD51AP1在肿瘤进展和耐药中的研究进展 LIU, Renwang LI, Mingbiao HU, Zixuan SONG, Zuoqing CHEN, Jun Zhongguo Fei Ai Za Zhi Review The genomic instability may lead to an initiation of cancer in many organisms. Homologous recombination repair (HRR) is vital in maintaining cellular genomic stability. RAD51 associated protein 1 (RAD51AP1), which plays a crucial role in HRR and primarily participates in forming D-loop, was reported as an essential protein for maintaining cellular genomic stability. However, recent studies showed that RAD51AP1 was significantly overexpressed in various cancer types and correlated with poor prognosis. These results suggested that RAD51AP1 may play a significant pro-cancer effect in multiple cancers. The underlying mechanism is still unclear. Cancer stemness-maintaining effects of RAD51AP1 might be considered as the most reliable mechanism. Meanwhile, RAD51AP1 also promoted resistance to radiation therapy and chemotherapy in many cancers. Thus, researches focused on RAD51AP1, and its regulatory molecules may provide new targets for overcoming cancer progression and treatment resistance. Here, we reviewed the latest research on RAD51AP1 in cancers and summarized its differential expression and prognostic implications. In this review, we also outlined the potential mechanisms of its pro-cancer and drug resistance-promoting effects to provide several potential directions for further research. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600754/ /pubmed/37985156 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Review
LIU, Renwang
LI, Mingbiao
HU, Zixuan
SONG, Zuoqing
CHEN, Jun
RAD51AP1在肿瘤进展和耐药中的研究进展
title RAD51AP1在肿瘤进展和耐药中的研究进展
title_full RAD51AP1在肿瘤进展和耐药中的研究进展
title_fullStr RAD51AP1在肿瘤进展和耐药中的研究进展
title_full_unstemmed RAD51AP1在肿瘤进展和耐药中的研究进展
title_short RAD51AP1在肿瘤进展和耐药中的研究进展
title_sort rad51ap1在肿瘤进展和耐药中的研究进展
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600754/
https://www.ncbi.nlm.nih.gov/pubmed/37985156
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.34
work_keys_str_mv AT liurenwang rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn
AT limingbiao rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn
AT huzixuan rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn
AT songzuoqing rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn
AT chenjun rad51ap1zàizhǒngliújìnzhǎnhénàiyàozhōngdeyánjiūjìnzhǎn